From GlobeNewswire: 2025-05-09 07:00:00

Boundless Bio announced initial data from the ongoing BBI-355 Phase 1/2 POTENTIATE trial for oncogene-amplified cancers expected in the second half of 2025. The Kinesin program is set for a mid-2025 development nomination with an IND filing in the first half of 2026. With a $138 million cash position, operations are funded through 2027.

The BBI-355 program, a potent CHK1 inhibitor for oncogene-amplified cancers, is enrolling patients for the Phase 1/2 POTENTIATE trial. Preliminary clinical proof-of-concept safety and efficacy data are forecasted for the latter half of 2025. Additionally, a new Kinesin program is in development, with a candidate nomination expected in mid-2025.

At the recent AACR Annual Meeting, preclinical data on Boundless’s RNR inhibitor, BBI-825, showed promise in delaying acquired resistance in colorectal cancer models. Financially, the company reported a cash position of $138.3 million as of March 31, 2025, with R&D expenses at $12.1 million and a net loss of $15.8 million for Q1 2025.

Boundless Bio, a clinical-stage oncology company, is focused on developing therapies for oncogene-amplified tumors by targeting extrachromosomal DNA. The company’s lead candidate, BBI-355, is an oral CHK1 inhibitor in a Phase 1/2 trial. In addition, Boundless is advancing its Kinesin program to target ecDNA segregation.

For investors, Boundless Bio can be contacted through Ben Flaum at [email protected] or Renee Leck at THRUST Strategic Communications. Media inquiries can be directed to Carly Scaduto at [email protected]. Financially, the company reported a net loss of $15.8 million for Q1 2025, with a cash position of $138.3 million as of March 31, 2025.



Read more at GlobeNewswire:: Boundless Bio Reports First Quarter 2025 Financial Results